Results 71 to 80 of about 5,401 (177)

Successful response to vismodegib therapy in locally advanced basal cell carcinoma with orbital involvement: A case report

Revista de la Facultad de Medicina Humana
Background: Basal cell carcinoma (BCC) is the most common skin cancer, often treated surgically. However, surgery may pose a high functional risk in cases of advanced orbital structures.
Mateo Aguirre-Flórez, Mauricio Arias-Flórez, Valeria López-Pulgarín, Mariana Alexandra Herrera-Caicedo, Daniel Millán-Morales   +4 more
doaj   +1 more source

The Contribution to the Assignment of Defined Daily Dose (DDD) to Antineoplastic Drugs of the Italian Working Group on DDD

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Purpose To report the experience of the Italian Working Group on DDD (Ita‐DDD‐wg) in assigning DDDs to a list of antineoplastic agents. Methods Active substances from the ATC L01 group with no assigned DDD and reimbursed at least once during 2021 by the Italian Healthcare Service were identified.
Angela Boccia, Giulia Hyeraci, Anna Girardi, Rosa Gini, Gianluca Trifirò, Ylenia Ingrasciotta, Andrea Spini, Valentina Ientile, Elisabetta Poluzzi, Giampiero Mazzaglia, Ippazio Cosimo Antonazzo, Casula Manuela, Elena Tragni, Olivia Leoni, Arianna Mazzone, Michele Ercolanoni, Martina Zanforlini, Ursula Kirchmayer, Belleudi Valeria, Marco Finocchietti, Francesco Barone‐Adesi, Giuseppe Roberto   +21 more
wiley   +1 more source

A Phase II Trial of Perioperative Oral Itraconazole for the Management of Low‐Risk Basal Cell Carcinoma

Experimental Dermatology, Volume 35, Issue 5, May 2026.
Neoadjuvant treatment with oral itraconazole for two months demonstrated significant responses in low‐risk basal cell carcinomas. This effect was associated with decreased tumour angiogenesis, presenting a favourable safety profile for patients. ABSTRACT Recently, new treatment strategies have been developed for advanced or metastatic basal cell ...
Rodrigo Pérez Pereira, Dienifer Hermann Sirena, Sérgio Jobim de Azevedo, Monique Maria Franco da Silva, Mariani Magnus da Luz Andrade, Charles Francisco Ferreira, Tiago Elias Heinen, Renato Marchiori Bakos   +7 more
wiley   +1 more source

Topical delivery of vismodegib using ablative fractional laser and micro-emulsion formulation in vitro

, 2019
Background and ObjectiveHedgehog inhibitors such as vismodegib are targeted drugs widely used for the treatment of basal cell carcinomas; however, their use is significantly limited by frequent systemic side effects due to oral administration route.
Merete Haedersdal, Lerche, Catharina M, Hædersdal, Merete, Gael Clergeaud, Clergeaud, Gael, Uffe H. Olesen, Lerche, Catharina M., Haedersdal, Merete, Thomas L. Andresen, Olesen, Uffe H., Andresen, Thomas L., Catharina M. Lerche   +11 more
core   +1 more source

Vismodegib [PDF]

Reactions Weekly, 2020
  +7 more sources

Cancer‐Associated Fibroblasts Functions as Multifunctional Architects of the Tumor Stroma and Represent Emerging Therapeutic Vulnerabilities

Advanced Science, Volume 13, Issue 24, 27 April 2026.
ABSTRACT Cancer‐associated fibroblasts (CAFs) are the predominant stromal components within the tumor microenvironment (TME), playing multifaceted roles in cancer progression through dynamic interactions with neoplastic and immune cells. Emerging evidence has revealed remarkable heterogeneity and plasticity of CAFs, which originate from diverse ...
Rujiao Liu, Lili Su, Shuiping Gao, Wenting Liu, Hongxia Wang   +4 more
wiley   +1 more source

Vismodegib and orbital excision for treating locally advanced basal cell carcinoma

, 2018
Daniel T Hogarty,1 Nicholas G Dewhurst,1 Benjamin Burt1–4 1Bendigo Eye Clinic, Bendigo, VIC, Australia; 2Royal Victorian Eye and Ear Hospital, Melbourne, VIC, Australia; 3Cosmetic Surgery for Women, Melbourne, VIC, Australia; 4Canberra ...
Burt B, Hogarty DT, Dewhurst NG
core  

Keratin positive micro-tumors present despite complete clinical response to vismodegib.

, 2022
A) Pathology results for excision samples after vismodegib treatment (error bars indicate 95% CI, n = 9 (left column), n = 18 (right column)), B) Pre- and post-vismodegib histology, C) Average total area and D) Average lesion size (pixels) of keratin 5 ...
Shelby P. Unsworth (8748393), Christopher A. Andrews (14204716), May P. Chan (14204719), Alon Kahana (197271), Curtis J. Heisel (8748390), Emily A. Eton (14204713), Christina F. Tingle (8748387), Scott C. Bresler (14204722)   +7 more
core   +1 more source

Pleural‐Based GLI1‐Altered Mesenchymal Tumor With ACTB‐GLI1 Fusion: A Rare Pulmonary Entity Mimicking Synovial Sarcoma

Thoracic Cancer, Volume 17, Issue 7, April 2026.
Pleural‐based GLI1‐altered mesenchymal tumor presenting as an incidental thoracic mass, characterized by biphasic morphology and ACTB‐GLI1 fusion, managed by thoracoscopic resection and surveillance. ABSTRACT GLI1‐altered mesenchymal tumors are exceptionally rare mesenchymal tumors, with recent molecular studies implicating GLI1 gene fusion or ...
Marco Lizwan, Li Xiao, Chun Yuen Chow, Hiu Yeung Lau, Boon‐Hean Ong   +4 more
wiley   +1 more source

The GPCR Connection: Linking Alzheimer's Disease and Glioblastoma

Journal of Cellular and Molecular Medicine, Volume 30, Issue 7, April 2026.
ABSTRACT Alzheimer's disease (AD) and glioblastoma multiforme (GBM) are biologically distinct age‐related brain disorders with opposing clinical phenotypes. AD is characterised by progressive neurodegeneration and cognitive decline, whereas GBM is characterised by aggressive cellular proliferation and a poor prognosis.
Ana B. Caniceiro, Sofia P. Agostinho, Luiz F. Piochi, Nícia Rosário‐Ferreira, Irina S. Moreira   +4 more
wiley   +1 more source